Does Benadryl Cause Dementia?

Key Takeaways

• Benadryl blocks histamine and acetylcholine, leading to sedation
• Anticholinergic effects increase fall risk in seniors
• Long‑term high anticholinergic exposure linked to dementia
• Observational studies show association, not causation
• Second‑generation antihistamines offer safer alternatives for older adults

Summary

Benadryl (diphenhydramine) is an over‑the‑counter antihistamine that also acts as an anticholinergic, causing drowsiness and other side effects, especially in older adults. Observational studies link long‑term high anticholinergic exposure to increased dementia risk, though causation remains unproven. The drug appears on the American Geriatrics Society’s Beers Criteria, prompting clinicians to favor newer, non‑sedating antihistamines for seniors. Short‑term, occasional use is generally considered low risk, but cumulative use should be avoided.

Pulse Analysis

Diphenhydramine’s dual action as an H1‑receptor antagonist and anticholinergic makes it uniquely sedating. By crossing the blood‑brain barrier it suppresses central histamine pathways that maintain wakefulness, while simultaneously blocking acetylcholine receptors involved in memory and attention. In older adults, age‑related reductions in hepatic clearance and blood‑brain barrier integrity amplify these central effects, turning a short‑term allergy remedy into a potential source of cognitive fog, dry mouth, urinary retention, and postural instability. This pharmacologic profile explains why the American Geriatrics Society’s Beers Criteria flag diphenhydramine as a medication to avoid in patients over 65.

Epidemiologic studies have repeatedly observed a correlation between cumulative anticholinergic exposure and higher rates of dementia. The landmark 2015 JAMA Internal Medicine cohort tracked over 3,000 seniors for seven years, finding that participants with anticholinergic use equivalent to a daily dose for more than three years faced a markedly increased dementia incidence. However, the analysis pooled diverse drug classes and relied on pharmacy dispensing records that often miss over‑the‑counter purchases, limiting causal inference. Subsequent meta‑analyses reinforce the association but also highlight heterogeneity across drug types, underscoring the need for randomized trials to disentangle drug‑specific risk from underlying health conditions.

For clinicians and caregivers, the pragmatic response is deprescribing diphenhydramine in favor of second‑generation antihistamines such as cetirizine, loratadine, or fexofenadine, which exhibit minimal central anticholinergic activity. These agents provide comparable allergy relief with once‑daily dosing and far fewer cognitive side effects, making them suitable for the aging population. When sleep aid is required, non‑pharmacologic sleep hygiene and evidence‑based therapies like cognitive‑behavioral insomnia treatment should be prioritized over off‑label diphenhydramine use. By reducing anticholinergic burden, healthcare providers can lower fall risk, preserve cognitive function, and align with broader geriatric stewardship initiatives.